Earnings Releases·Nov 9, 2026, 4:05 PM ET

Immunome — Third Quarter 2026 Earnings Summary

Reported a net loss of $85.8 million for Q3 2026, widening from $57.5 million in the prior year period, driven by a 50% increase in total operating expenses to $90.4 million.
Cash, cash equivalents, and marketable securities totaled $461.6 million as of September 30, 2026, with management projecting this position will fund operations into 2028.
Advance toward regulatory milestones includes a Varegacestat PDUFA target date of April 28, 2027, following FDA NDA acceptance in July 2026 and EMA MAA validation in October 2026.
Pipeline progress includes IND clearance for IM-1340 in September 2026, first patient dosing for IM-1617 and IM-3050 in mid-2026, and expectations to initiate a Phase 1 trial for IM-1340 and submit an IND for IM-1335 by year-end 2026.
Updated clinical data for IM-1021 showed objective response rates of 53% in B-cell non-Hodgkin lymphoma and 64% in diffuse large B-cell lymphoma, with further updates expected at the ASH Annual Meeting in December 2026.